Patient characteristics at enrollment in the training cohort
| Characteristic . | n . | % . |
|---|---|---|
| Age, y | ||
| ≤60 | 20 | 83.3 |
| >60 | 4 | 16.7 |
| Sex | ||
| Male | 15 | 62.5 |
| Female | 9 | 37.5 |
| ECOG PS | ||
| 0-1 | 22 | 91.7 |
| 2 | 2 | 8.3 |
| Ann Arbor stage | ||
| I-II | 13 | 54.2 |
| III-IV | 11 | 45.8 |
| Disease status | ||
| Relapsed | 11 | 45.8 |
| Newly diagnosed | 13 | 54.2 |
| Primary tumor location | ||
| UADT | 19 | 79.2 |
| Extra-UADT | 4 | 20.8 |
| Distant involvement | ||
| Skin | 4 | 16.7 |
| Lung | 2 | 8.3 |
| Bone | 3 | 12.5 |
| Distant lymph node | 3 | 12.5 |
| Adrenal gland | 1 | 4.2 |
| B symptoms | ||
| Yes | 14 | 58.3 |
| No | 20 | 41.7 |
| Primary tumor invasion | ||
| Yes | 22 | 91.7 |
| No | 2 | 8.3 |
| Elevated LDH | ||
| Yes | 13 | 54.2 |
| No | 11 | 45.8 |
| Serum EBV DNA | ||
| Positive | 15 | 62.5 |
| Negative | 7 | 29.2 |
| Not available | 2 | 8.3 |
| PD-L1 expression, % | ||
| 0 | 3 | 12.5 |
| ≥1 and <50 | 9 | 37.5 |
| ≥50 | 12 | 50.0 |
| IPI score | ||
| 0-1 | 12 | 50.0 |
| 2 | 7 | 29.2 |
| 3 | 5 | 20.8 |
| PINK score | ||
| 0 | 9 | 37.5 |
| ≥1 | 15 | 62.5 |
| PINKE score | ||
| ≤1 | 10 | 41.6 |
| >1 | 14 | 58.4 |
| Characteristic . | n . | % . |
|---|---|---|
| Age, y | ||
| ≤60 | 20 | 83.3 |
| >60 | 4 | 16.7 |
| Sex | ||
| Male | 15 | 62.5 |
| Female | 9 | 37.5 |
| ECOG PS | ||
| 0-1 | 22 | 91.7 |
| 2 | 2 | 8.3 |
| Ann Arbor stage | ||
| I-II | 13 | 54.2 |
| III-IV | 11 | 45.8 |
| Disease status | ||
| Relapsed | 11 | 45.8 |
| Newly diagnosed | 13 | 54.2 |
| Primary tumor location | ||
| UADT | 19 | 79.2 |
| Extra-UADT | 4 | 20.8 |
| Distant involvement | ||
| Skin | 4 | 16.7 |
| Lung | 2 | 8.3 |
| Bone | 3 | 12.5 |
| Distant lymph node | 3 | 12.5 |
| Adrenal gland | 1 | 4.2 |
| B symptoms | ||
| Yes | 14 | 58.3 |
| No | 20 | 41.7 |
| Primary tumor invasion | ||
| Yes | 22 | 91.7 |
| No | 2 | 8.3 |
| Elevated LDH | ||
| Yes | 13 | 54.2 |
| No | 11 | 45.8 |
| Serum EBV DNA | ||
| Positive | 15 | 62.5 |
| Negative | 7 | 29.2 |
| Not available | 2 | 8.3 |
| PD-L1 expression, % | ||
| 0 | 3 | 12.5 |
| ≥1 and <50 | 9 | 37.5 |
| ≥50 | 12 | 50.0 |
| IPI score | ||
| 0-1 | 12 | 50.0 |
| 2 | 7 | 29.2 |
| 3 | 5 | 20.8 |
| PINK score | ||
| 0 | 9 | 37.5 |
| ≥1 | 15 | 62.5 |
| PINKE score | ||
| ≤1 | 10 | 41.6 |
| >1 | 14 | 58.4 |
EBV, Epstein-Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance score; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PINK, prognostic index for NK cell lymphoma; PINKE, PINK plus EBV; UADT, upper aerodigestive tract.